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a b s t r a c t
Calcinosis is a connective tissue disorder classifi ed into the following four types: metastat-
ic; idiopathic; iatrogenic and dystrophic. Dystrophic calcinosis can occur, for example, in 
dermatomyositis, mainly in juvenile dermatomyositis, and is characterized by an abnormal 
deposition of calcium salts in affected skin, subcutaneous tissues, and muscles or tendons, 
with normal serum levels of calcium and phosphate. The treatment of calcinosis in der-
matomyositis remains a challenge, with few descriptions in the literature of low scientifi c 
evidence. So far, no therapy has proved to be highly effective in the combat and resolution 
of that comorbidity. The present study discusses the concept of calcinosis, particularly in 
dermatomyositis, as well as its treatment described in the literature.
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Concept of calcinosis
Calcinosis is a connective tissue disorder classifi ed into the 
four following types: metastatic; idiopathic; iatrogenic and 
dystrophic.1,2 Metastatic calcinosis refers to the deposition 
of calcium salts in normal tissues, with increased serum 
levels of calcium and/or phosphate, whose product is ≥ 70.1,2 
Idiopathic calcifi cation occurs in normal tissues, with nor-
mal serum levels of calcium and phosphate.1,2 Iatrogenic 
calcinosis includes the hypersensitivity reaction, which 
usually begins with livedo reticularis rapidly progressing to 






r e s u m o
Calcinose é uma afecção do tecido conjuntivo classifi cada em quatro tipos: metastática, 
idiopática, iatrogênica e distrófi ca. Esta última é o que acontece, por exemplo, em derma-
tomiosite, principalmente na forma juvenil, e é caracterizada por uma deposição anormal 
de sais de cálcio em pele afetada, tecidos subcutâneos, músculos ou tendões, sendo os 
níveis séricos de cálcio e fósforo normais. O tratamento da calcinose em dermatomiosite 
continua sendo um desafi o, havendo poucas descrições na literatura, de pouca evidência 
científi ca. Não se apresenta, até o momento, nenhuma terapia altamente efi caz no combate 
e resolução dessa comorbidade. No presente trabalho, abordamos o conceito de calcinose, 
particularmente em dermatomiosite, assim como o seu tratamento descrito na literatura.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Atualização na terapêutica da calcinose em dermatomiosite
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the formation of skin ulcers and necrosis; it is more com-
monly reported in patients with chronic renal failure on he-
modialysis.1 Dystrophic calcinosis is the abnormal deposi-
tion of calcium salts in affected skin, subcutaneous tissue, 
and muscles or tendons, with normal serum levels of cal-
cium and phosphate.2,3 Dystrophic calcinosis can occur, for 
example, in dermatomyositis (DM).
Calcinosis in dermatomyositis
In patients with DM, calcinosis is much more frequent in the 
pediatric age group, being present in 10%–70% of the cas-
es.4–9 In adults, it is reported in about 20% of the patients,10,11 
and can precede the diagnosis of DM or even appear years 
after that. Usually, calcinosis appears between the fi rst and 
third years of the disease.6
In DM, calcinosis can present as follows: (a) hard nod-
ules or plaques in subcutaneous or periarticular regions; 
(b) tumors; (c) deposits in the intermuscular fascia, lead-
ing to mobility limitation of the affected muscles; (d) severe 
dystrophic calcifi cation similar to an exoskeleton; and (e) 
mixed form.4 Calcinosis can have a negative impact on the 
patients’ quality of life, causing weakness, functional dis-
ability, joint contractures, muscle atrophy, skin ulcers, and, 
consequently, local pains and secondary infections.
Pathogenesis and risk factors
The etiopathogenesis of calcinosis in DM is unknown. Based 
on case reports, calcinosis is believed to result from the in-
tracellular accumulation of calcium secondary to a change 
in cell membrane. It can be triggered by trauma and/or 
chronic infl ammation,12,14–31 such as in cases nonresponsive 
to corticotherapy, in the presence of generalized cutaneous 
vasculitis, important muscle weakness, and persistent el-
evation in muscle enzymes.4–6,13–15
The hypothesis of infl ammation at the calcinosis site is 
plausible, because several authors have shown the presence 
of cells and pro-infl ammatory cytokines, such as IL-116 and 
TNF-alpha,17 and a variety of proteins related to mineraliza-
tion, such as osteopontin, osteonectin, bone sialoprotein 
and hydroxyapatite,18 at the calcinosis site.17 It has also been 
associated with the presence of antibodies against the 140 
kDa protein19 and with TNF-alpha-308A polymorphism.16
Fisler et al.20 have studied 35 cases and reported an as-
sociation between calcinosis and a delay in the diagnosis 
and/or beginning of treatment, increased muscle enzymes, 
and prolonged disease duration. Similarly, Pachman et al.13 
have observed calcinosis and a delay in disease diagnosis. 
However, Sallum et al.6 have reported the association of the 
development of calcifi ed nodules, systemic involvement of 
the myopathy and aggressive use of medicaments. Bowyer 
et al.4 have shown that inadequate initial therapy plays an 
important role in the development of calcinosis. In addi-
tion, as previously mentioned, calcinosis is less frequent in 
adults with DM, raising the possibility that age-dependent 
factors could infl uence the risk of developing ectopic calci-
fi cations.21
Treatment of calcinosis in dermatomyositis
The present study systematically review the treatments report-
ed for calcinosis in DM. A literature search was conducted in 
the MEDLINE database by using the following terms: calcinosis 
and dermatomyositis.
Except for 14 cases reported as having spontaneous reso-
lution,1–4,9,22–24 calcinosis in DM tends to increase with disease 
progression. An early and aggressive therapeutic intervention 
against DM activity has been suggested to possibly reduce the 
musculocutaneous sequelae of the disease, including calcino-
sis itself.20
However, so far, no consensus has been achieved about the 
effective treatment for calcinosis in DM, and the data avail-
able in the literature are based only on reports and/or case 
series, particularly in juvenile DM. The use of the following 
medications has been mentioned: bisphosphonates; proben-
ecid; warfarin; aluminum hydroxide; colchicine; diltiazem; 
and infl iximab.
Ambler et al.25 have reported the case of an 8-year-old child 
with chronic juvenile DM, whose calcinosis was completely re-
solved after using alendronate (10 mg/day) for 12 months. The 
patient had previously received diltiazem (15 mg, 2x/day) and 
probenecid (500 mg, 2x/day), with no resolution of the calcino-
sis. Similarly, Mukamel et al.26 have reported an improvement 
in calcinosis in a 6-year-old patient with juvenile DM by intro-
ducing alendronate (10 mg/day) for 12 months.
Mori et al.27 have reported the use of etidronate (800 mg/
day) in a 26-year-old patient with DM, who, in addition to cal-
cinosis, had osteoporosis. Those authors have reported the 
regression of calcinosis three months after beginning drug 
therapy. In addition, a signifi cant improvement was observed 
in densitometric values after a three-year follow-up. Never-
theless, Metzger et al.28 have assessed the effect of etidronate 
in three patients with DM and calcinosis for 12 months, no 
satisfactory effect being observed.
The use of pamidronate has also been described.29,30 Three 
patients with juvenile DM received pamidronate at the dos-
age of 1 mg/kg/day for three consecutive days, repeated every 
month. A satisfactory response was observed in all cases, in-
cluding one complete resolution of the calcinosis.
Based on the principle that probenecid might reduce the lo-
cal infl ammatory process, it has been used, but the results are 
controversial.8,9,31–33
Fuchs et al.34 have described a case of juvenile DM with cal-
cinosis in the prepatellar region, accompanied by infl ammation 
and localized cutaneous ulcer. An improvement in the cutane-
ous lesions was observed two months after using colchicine at 
the dosage of 1 mg/day.
Based on the theory of having an inhibitory effect on the cal-
cium channels of the cell membrane, diltiazem has proved to 
be, mainly in cases of juvenile DM, a therapeutic alternative.35–39 
Its dosages have varied from 30–180 mg/day, and that drug was 
introduced to patients whose treatments with bisphospho-
nate and aluminum hydroxide did not succeed. All cases de-
scribed35–39 showed an excellent response in follow-ups ranging 
from 6–10 months.
Miyamae et al.40 have assessed the benefi cial effect of tha-
lidomide in one 14-year-old female patient with juvenile DM 
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for ten years, who had previously undergone pulse therapy 
with methylprednisolone, cyclophosphamide, cyclosporine, 
azathioprine, probenecid, magnesium hydroxide, aluminum 
hydroxide, in addition to infl iximab (suspended due to adverse 
effects) and etanercept for disease activity and calcinosis pro-
gression. Later, at the age of 12 years, thalidomide was intro-
duced (1.3 mg/kg/day, orally, in the fi rst month, and, then, 2 mg/
kg/day), the response being satisfactory.
Older descriptions have evidenced good results with alumi-
num hydroxide for patients with juvenile DM, no adverse ef-
fects being reported.41–44 Nakagawa et al.42 have reported a case 
with an almost complete resolution of calcinosis after eight 
months of treatment.
Vitamin K plays an important role in calcium binding with 
bones and tissues.23 Based on this concept, Berger et al.45 and 
Matsuoka et al.46 have used low doses of warfarin to patients 
with juvenile DM and nodular calcinosis. Those authors have 
reported a reduction in the size of the lesions after using war-
farin for three years.
Regression of cutaneous calcinosis following intralesional 
infi ltration of corticosteroid has been described by Al-Mayouf et 
al.47 in a 10.5-year-old patient, preceded by use of methotrexate 
and corticosteroid for disease activity. For the calcinosis located 
in one of the elbows, colchicine and pamidronate infusion ev-
ery three months (total of fi ve doses) were unsuccessfully used. 
Corticosteroid infi ltration using the barbotage technique was 
performed, with consequent regression of the calcinosis.
Surgical procedures have been reserved to extensive areas 
of calcifi cation,48,49 with incision and local drainage, and have 
shown satisfactory results.
In the era of biological therapy, infl iximabe has been used at 
the dosage of 3 mg/kg (same schedule for rheumatoid arthritis) 
to treat fi ve patients with juvenile DM refractory to previously 
proposed treatments; all cases had a positive response, with 
calcinosis regression in periods ranging from 8–30 months af-
ter beginning treatment.50 Arabshahi et al.51 have reported the 
use of abatacept (10 mg/kg, monthly, after fortnightly applica-
tion in the fi rst month) and sodium thiosulfate (topic, initially 
at 3%, and, then, at 10%, fortnightly) to a 14-year-old patient 
with juvenile DM for three years, refractory to corticosteroid, 
tacrolimus and intravenous human immunoglobulin, who had 
progressive calcinosis and ulcerated cutaneous lesions. The 
therapy instituted determined a reduction in musculocutane-
ous infl ammation and calcinosis regression.
In conclusion, the treatment of calcinosis in both adult 
and juvenile DM remains a challenge, with few descriptions in 
the literature of low scientifi c evidence. So far, no therapy has 
proved to be highly effective in the combat and resolution of 
that comorbidity.
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